Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study

Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), Gianluigi Reda(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Wilma Barcellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Antonino Neri(University of Milan), Pellegrino Musto(University of Bari Aldo Moro), Umberto Gianelli(University of Milan), Anna Bossi, Barbara Sarina(IRCCS Humanitas Research Hospital), Angelo Gardellini(Ospedale Valduce), Maria Cristina Pasquini(Azienda Ospedaliera Ospedale Maggiore)
Leukemia
July 30, 2009
10.1038/leu.2009.148
Cited by 38

Related Papers

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
|Leukemia|2009|877
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
|Blood|2009|433
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial
|Journal of Clinical Oncology|2016|394